Abstract
Author reports the efficacy, pharmacokinetics and metabolism of ALK-inhibitor first generation, indication criteria, application form, safety profile as well as results of clinical studies on crizotinib targeted on the therapy of non small cell lung cancer. Accordingly of actual experience, crizotinib is effective and safe therapeutic option for the ALK-translocated NSCLCwith relatively narrow indication spectrum.